Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

PPA Category III status for safety in nasal decongestants tentatively decided -- FDA.

This article was originally published in The Tan Sheet

Executive Summary

PPA TO BE DESIGNATED CATEGORY III FOR SAFETY IN OTC NASAL DECONGESTANT and weight control products in upcoming proposed rules while additional safety data on the ingredient are being collected, FDA said in a May 17 letter to Caprice-Greystoke. The agency explained that its position on phenylpropanolamine hydrochloride (PPA)'s status in the pending proposed rules is "tentative." The letter responds to the company's third citizen petition on PPA, dated Dec. 8, 1995.
Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

PS085491

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel